Novelwise Pharma Announces Initiation of Phase Ib/II Clinical Trial of NBM-BMX in Newly Diagnosed Glioblastoma Patients

Novelwise Pharmaceutical Corp. announced that its investigational drug NBM-BMX has officially entered a Phase Ib/II clinical trial in patients with newly diagnosed glioblastoma (GBM). The trial received approval from the U.S. Food and Drug Administration (USFDA) on January 4, 2023, marking an important milestone in the company's R&D progress.

Phase I trials of NBM-BMX, conducted in both Taiwan and the United States, demonstrated a favorable safety profile along with encouraging preliminary efficacy signals. These results not only support the drug's continued clinical development but also enhance its value as a promising global new drug candidate.

Glioblastoma is among the most aggressive and challenging brain cancers worldwide, with more than 60% of newly diagnosed patients failing to respond to standard therapies. NBM-BMX offers a novel therapeutic strategy with the potential to address this critical unmet medical need by providing safer and more effective treatment options.

Novelwise Pharma stated that, as the clinical program advances, the company will continue to strengthen international collaborations, accelerate drug development and commercialization, and build long-term competitive advantages through diversified strategies-creating sustainable value for investors and partners alike.